Peptide Schedule
AOD-960416 residuesYLRIVQCRSVEGSCGFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

AOD-9604

Weight LossInjectionPhase 2Grade A~2 hours half-life
Fat LossBody RecompositionWeight Management12 weeks on / 4 weeks off

Benefits

Targeted fat loss without muscle growth effects
Does not affect blood sugar or insulin
GRAS safety status
No desensitization with continued use
Supports body recomposition
Half-Life
~2 hours
Route
Injection
Frequency
Daily
Vial Sizes
5mg
BAC Water
2mL
Safety Grade
Grade A
Open AOD-9604 Dosage Calculator
Calculate exact syringe units for your vial and dose

About AOD-9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) specifically designed for fat metabolism. Unlike full HGH, it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or growth. It has GRAS (Generally Recognized As Safe) status in the US.

Who Should Consider AOD-9604

  • Adults with BMI ≥30 seeking non-hormonal fat loss support
  • Individuals who want fat reduction without IGF-1 or blood sugar effects
  • Adults looking for a GRAS-status peptide option for body recomposition
  • Patients who cannot tolerate GLP-1 receptor agonists
  • Adults with stubborn adipose deposits resistant to diet and exercise

How AOD-9604 Works

AOD-9604 mimics the lipolytic region of human growth hormone (fragment 177-191). It stimulates the beta-3 adrenergic receptor to trigger fat breakdown (lipolysis) while simultaneously inhibiting lipogenesis — the process of converting food into stored body fat. Unlike full HGH, it does not compete for the GH receptor, so it has no effect on blood sugar, growth, or IGF-1 levels.

What to Expect

Weeks 1-2

Body adjusts to the peptide. No visible fat loss yet. Mild injection site redness may occur. Establish consistent fasted morning dosing routine.

Weeks 3-4

Early metabolic shifts begin. Some users notice reduced abdominal bloating. Fat oxidation rates start to increase, though scale weight may not change significantly.

Weeks 5-8

Measurable fat loss becomes apparent, particularly in the midsection. Clothes may fit differently. Average loss of 1-2 kg of fat tissue reported in clinical data at comparable timepoints.

Weeks 9-12

Continued steady fat loss. Clinical trial subjects on 1 mg/day lost an average of 2.6 kg over 12 weeks. Body composition improvements are visible. No receptor desensitization observed.

Weeks 12-16+

Ongoing fat metabolism support. Results plateau as body reaches a new set point. Can extend beyond 12 weeks if well-tolerated. Pair with exercise and caloric control for best outcomes.

Dosing Protocol

LevelDose / InjectionFrequency
Beginner200mcgDaily
Moderate300mcgDaily
Aggressive500mcgDaily

Note: HGH fragment 177-191. Fat loss without growth effects. GRAS status. Dose on empty stomach.

How to Inject AOD-9604

Inject subcutaneously into abdominal fat, ideally first thing in the morning on an empty stomach. Wait 30 minutes before eating. Rotate injection sites to prevent lipodystrophy.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

No receptor desensitization reported, but cycling is still recommended. Can be run longer if well-tolerated.

Pharmacokinetics

Half-Life
2h
Bioavailability
SC: estimated higher than oral (~40% oral in animal models)
Tmax
~15-30 minutes (SC)
Data Confidence
low

Source: Estimated from rapid peptide degradation kinetics observed in metabolic studies (PMID 11146367)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated. Mild injection site reactions possible. Headache and nausea rarely reported.

Contraindications

  • Pregnancy or breastfeeding — no safety data in these populations
  • Active malignancy or history of cancer — effects on tumor growth not studied
  • Known hypersensitivity to AOD-9604 or any excipients
  • Children and adolescents under 18 — not studied in pediatric populations

Drug Interactions

  • Insulin and oral hypoglycemics — although AOD-9604 does not directly affect blood sugar, monitor glucose when combining with diabetes medications
  • Thyroid medications — fat metabolism changes may alter thyroid hormone requirements; monitor levels
  • Other lipolytic agents (e.g., growth hormone, clenbuterol) — potential additive effects on fat mobilization; use with caution
  • Anticoagulants — no known interaction, but as with all injectable peptides, monitor for injection site bruising

Storage & Stability

Before Reconstitution
Room temperature up to 3 months, refrigerated up to 2 years
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F) after reconstitution

Molecular Profile

Amino Acids
16
Molecular Weight
1,817.12 Da
Sequence
YLRIVQCRSVEGSCGF
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

Related Peptides

Semaglutide
Weight Loss
Tirzepatide
Weight Loss
HGH 191AA
Growth Hormone

References

  1. Effects of hGH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice and beta-3-AR knock-out mice (Endocrinology 2001)PubMed 11713213
  2. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with hGH or a modified C-terminal fragment (Int J Obes 2001)PubMed 11673763
  3. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (J Pharmacol Exp Ther 2000)PubMed 11146367
  4. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism (Obes Res 2000)PubMed 10950816
  5. Detection and in vitro metabolism of AOD9604 (Drug Test Anal 2015)PubMed 25208511
  6. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health (J Endocrinol Metab)Review

Related Resources

AOD-9604 CalculatorBest Peptides for Weight LossWeight Loss StackAdvanced Weight Loss Stack

Frequently Asked Questions